hotspot -WSS

hotspot

author：hotspot 2025-09-29 09:29:56 - browse：346

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： ARCH Venture Partners is raising $3 billion for a life sciences fund

WSS

With Wegovy coverage, Medicare patients may face high costs

'Patient friction coefficient' can gauge a clinical trial's patient burden

Mirador, a new biotech startup, launches with $400 million

Do digital therapeutics have a future in medicine?

Readout Newsletter: Illumina, CRISPR, Regeneron

Woodcock on FDA’s accelerated approval and her next chapter

entertainment

hotspot

entertainment

Cancer drug shortages should be causing more outrage

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Novavax promises a turnaround & Lilly roils the obesity market

Medicare Advantage insurers pressure Biden for bigger payments

New air purifier tech could be key to improving indoor air quality

New Ultima Genomics DNA sequencer can read genome for $100

Malaria cases in Florida and Texas: Here’s what you need to know

Yancopoulos of Regeneron works to expand Dupixent success

Peter Hotez and the public health issue of online harassment

'Patient friction coefficient' can gauge a clinical trial's patient burden

focus

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Cognito secures funding to test medical device for Alzheimer's

Time to name cancers by genetics, not organ of origin, expert says

Some dementia cases could be undiagnosed liver disease

Commercial surrogacy can be ethical, despite pope’s claims

Testing GLP

Wikipedia

focus

explore

knowledge